Hepion Pharmaceuticals, Inc. (HEPA)

Market Cap	12.87M +1,481.9%
Revenue (ttm)	n/a
Net Income	-3.19M
EPS	-0.25
Shares Out	98.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163
Open	0.1160
Previous Close	0.1223
Day's Range	0.1120 - 0.1310
52-Week Range	0.0341 - 0.2200
Beta	1.69
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: HEPA

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error